Detailed process map ares being undertaken with the Pharmacy teams at the WGH, RGH ,St Johns and the RIE.

The anticipated benefits from improvement opportunities identified are:

·         Reduction in the number of sites undertaking overlabelling and associated staff time released to clinical areas for direct patient pharmaceutical care

·        Rationalisation and agreement of the number of products lines and variations produced

·        Increase in batch production size and reduction in the frequency of batch productions for same line

·        Optimal stock holding and turn over

·        Reduction in the number of labelling errors

·        Any associated financial benefits from the above